Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma

  • Technology appraisal guidance
  • TA1059
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence